Page 11 - அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Multiple hematomas in a coronavirus disease-19 patient

Background: Anticoagulant therapy for patients with severe coronavirus disease (COVID-19) pneumonia is considered to improve the hypercoagulable and inflammatory state. However, bleeding complications should also be considered. Case Presentation: A 77-year-old man with a history of falls was diagnosed with COVID-19. Owing to his severe condition, he was intubated and transferred to our hospital for intensive care. Favipiravir, tocilizumab, unfractionated heparin, and ART-123 were administered to treat COVID-19 and manage the antithrombotic prophylaxis for paroxysmal atrial fibrillation (Af). On the 6th day after admission, a hematoma was noted on the left chest wall. Computed tomography (CT) revealed multiple hematomas, including hematomas on his chest wall and obturatorius internus muscle. Emergency angiography transcatheter embolization (TAE) was performed. The patient was transferred to another hospital 23 days after TAE, without complications.

United statesAmerican society of hematologyAmerican societySepsis coagulopathy asahi recombinantஒன்றுபட்டது மாநிலங்களில்அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜிஅமெரிக்கன் சமூகம்

Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX? (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe

Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX? (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCraig tendlerDaratumumab pomalidomideChristopher deloreficeVelcade melphalanBortezomib melphalanJennifer mcintyreNoah reymondVelcade bortezomib melphalanGlobal medical affairsJanssen biotech incAmerican society of hematology annual meetingAmerican society of clinical oncologyJanssen research developmentJanssen pharmaceutical companies

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control

Share this article Share this article RARITAN, N.J., May 19, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA ® plus venetoclax were alive and progression-free at two years. 1 Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL). 1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These data reinforce the long-term survival benefits and well-established safety profile of single-agent IMBRUVICA

United statesCraig tendlerJennifer mcintyrePaolo ghiaChristopher deloreficeBernadette kingChristie corbettNone of the janssen pharmaceutical companiesGlobal medical affairsJanssen biotech incAmerican society of clinical oncologyDrug administrationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commission

Janssen: IMBRUVICA (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukaemia Demonstrates High Rates of Disease Control

Janssen: IMBRUVICA (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukaemia Demonstrates High Rates of Disease Control
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCraig tendlerNoah reymondJennifer mcintyrePaolo ghiaChristopher deloreficeEdmond chanGlobal medical affairsJanssen biotech incAmerican society of clinical oncologyEuropean hematology associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyAmerican society of clinical oncology annual meeting

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesCraig tendlerJennifer mcintyrePaolo ghiaChristopher deloreficeBernadette kingChristie corbettNone of the janssen pharmaceutical companiesGlobal medical affairsJanssen biotech incAmerican society of clinical oncologyDrug administrationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commission